Foresight CLARITY
Ultra-sensitive ctDNA molecular residual disease assay using PhasED-Seq phased-variant detection, with strong current use in B-cell lymphoma clinical programs.
- Developer
- Foresight Diagnostics
- Intended use
- Mrd
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue, Plasma
- Molecular modality
- DNA mutation
- Current version
- Foresight CLARITY current LDT (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.